Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

680
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
680
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

3.4K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.4K
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

356
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
356
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

792
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
792
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

358
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
358

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AgNPs-induced nanoelicitation: enhancing Eugenol, Rosmarinic Acid, antioxidant defense and gene expression in <i>Ocimum tenuiflorum</i>.

Physiology and molecular biology of plants : an international journal of functional plant biology·2026
Same author

VP1 region-based molecular characterization of foot-and-mouth disease virus serotype O from clinical cases in Haryana, India.

BMC veterinary research·2025
Same author

Modulation of Nrf-2/HO-1/HIF-1α/TFAM pathways by Arbutin in rat model of cerebral ischemic stroke.

Molecular and cellular neurosciences·2025
Same author

Systematic follow-up investigation of NSP seroreactors and in-contact cattle and buffaloes for foot-and-mouth disease virus using probang sampling.

BMC veterinary research·2025
Same author

The role of nanoparticles in transforming plant genetic engineering: advancements, challenges and future prospects.

Functional & integrative genomics·2025
Same author

Prevalence of psychiatric disorders among the adult population in a rural community of Jammu, India: a cross-sectional study.

Frontiers in psychiatry·2024

Related Experiment Video

Updated: Apr 14, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

2.1K

Cycloserine induced psychosis with hepatic dysfunction.

Vishal R Tandon1, Neelam Rani1, Roshi1

  • 1Department of Pharmacology and Therapeutics, Government Medical College, Jammu, Jammu and Kashmir, India.

Indian Journal of Pharmacology
|April 17, 2015
PubMed
Summary
This summary is machine-generated.

Cycloserine, a second-line tuberculosis drug, can cause psychosis and liver problems. This case highlights a rare adverse effect of cycloserine treatment in multidrug-resistant tuberculosis patients.

Keywords:
Anti-tubercular treatmentcycloserinemultidrug resistant tuberculosispsychosis

More Related Videos

Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae
09:05

Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae

Published on: April 18, 2016

30.3K
Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

12.0K

Related Experiment Videos

Last Updated: Apr 14, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

2.1K
Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae
09:05

Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae

Published on: April 18, 2016

30.3K
Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

12.0K

Area of Science:

  • Pharmacology
  • Neurology
  • Hepatology

Background:

  • Increasing prevalence of multidrug-resistant tuberculosis necessitates the use of second-line anti-tubercular drugs.
  • Cycloserine is frequently prescribed for tuberculosis, but its neuropsychiatric side effects are less documented than other agents.
  • Existing literature reports psychosis associated with isoniazid and ethambutol, but rarely with cycloserine.

Observation:

  • A patient developed psychosis during treatment with cycloserine.
  • The patient also exhibited signs of hepatic dysfunction concurrently with the neuropsychiatric symptoms.
  • This presentation is unusual, as cycloserine-induced psychosis is infrequently reported.

Findings:

  • This report details the first documented case of cycloserine-induced psychosis accompanied by hepatic dysfunction.
  • The findings suggest a potential link between cycloserine use and the development of both psychosis and liver injury.
  • Neuropsychiatric adverse events associated with cycloserine should be closely monitored.

Implications:

  • Clinicians should be aware of the potential for cycloserine to induce psychosis and hepatic dysfunction.
  • Early recognition and management of these adverse effects are crucial for patient outcomes.
  • Further research is warranted to elucidate the mechanisms underlying cycloserine's toxicity and to establish monitoring guidelines.